AU2008236562B2 - Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha - Google Patents

Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha Download PDF

Info

Publication number
AU2008236562B2
AU2008236562B2 AU2008236562A AU2008236562A AU2008236562B2 AU 2008236562 B2 AU2008236562 B2 AU 2008236562B2 AU 2008236562 A AU2008236562 A AU 2008236562A AU 2008236562 A AU2008236562 A AU 2008236562A AU 2008236562 B2 AU2008236562 B2 AU 2008236562B2
Authority
AU
Australia
Prior art keywords
pyrazolo
piperazin
methyl
phenyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008236562A
Other languages
English (en)
Other versions
AU2008236562A1 (en
Inventor
Peter Lamb
David Matthews
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2008236562A1 publication Critical patent/AU2008236562A1/en
Application granted granted Critical
Publication of AU2008236562B2 publication Critical patent/AU2008236562B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008236562A 2007-04-10 2008-04-09 Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha Ceased AU2008236562B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92289907P 2007-04-10 2007-04-10
US60/922,899 2007-04-10
PCT/US2008/004573 WO2008124161A1 (en) 2007-04-10 2008-04-09 Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha

Publications (2)

Publication Number Publication Date
AU2008236562A1 AU2008236562A1 (en) 2008-10-16
AU2008236562B2 true AU2008236562B2 (en) 2013-11-07

Family

ID=39627802

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008236562A Ceased AU2008236562B2 (en) 2007-04-10 2008-04-09 Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha

Country Status (31)

Country Link
US (1) US8513266B2 (enExample)
EP (1) EP2139484B9 (enExample)
JP (3) JP2010523670A (enExample)
KR (1) KR101626435B1 (enExample)
CN (2) CN102727498B (enExample)
AU (1) AU2008236562B2 (enExample)
BR (1) BRPI0810206A2 (enExample)
CA (1) CA2683641C (enExample)
CO (1) CO6251254A2 (enExample)
CR (1) CR11100A (enExample)
DK (1) DK2139484T3 (enExample)
DO (1) DOP2009000243A (enExample)
EA (1) EA020022B1 (enExample)
EC (1) ECSP099724A (enExample)
ES (1) ES2430614T3 (enExample)
HN (1) HN2009003002A (enExample)
HR (1) HRP20130688T1 (enExample)
IL (1) IL201284A (enExample)
MA (1) MA31358B1 (enExample)
ME (1) ME00936B (enExample)
MX (1) MX2009010930A (enExample)
MY (1) MY150697A (enExample)
NZ (1) NZ580110A (enExample)
PL (1) PL2139484T3 (enExample)
PT (1) PT2139484E (enExample)
RS (1) RS52939B (enExample)
SI (1) SI2139484T1 (enExample)
TN (1) TN2009000400A1 (enExample)
UA (1) UA100979C2 (enExample)
WO (1) WO2008124161A1 (enExample)
ZA (1) ZA200906764B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
KR20140105621A (ko) * 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 PI3Kα의 피리도피리미디논 억제제
EP1931645B1 (en) * 2005-10-07 2014-07-16 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
KR101626435B1 (ko) 2007-04-10 2016-06-01 엑셀리시스, 인코포레이티드 Pi3k 알파의 피리도피리미디논 억제제를 이용한 암 치료 방법
US8481001B2 (en) * 2007-04-11 2013-07-09 Exelixis, Inc. Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer
CA2734486A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR072938A1 (es) 2008-08-20 2010-09-29 Southern Res Inst Derivados de piridina y pirimidina azosustituidos y su uso en el tratamiento de infecciones virales
EP2326626B1 (en) 2008-08-20 2013-10-16 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022125A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
UY33221A (es) 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
WO2012027536A1 (en) * 2010-08-26 2012-03-01 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
AU2011302196B2 (en) 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
WO2012065019A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
US9441013B2 (en) * 2011-05-17 2016-09-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
CA2843222A1 (en) * 2011-07-28 2013-01-31 Genentech, Inc. Pik3ca h1047r knock-in non-human animal breast cancer model
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
WO2013067141A1 (en) 2011-11-01 2013-05-10 Exelixis, Inc. N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies
EP2776837A4 (en) * 2011-11-11 2015-05-20 Intellikine Llc COMBINATION OF KINASEINHIBITORS AND THEIR USE
WO2013101964A1 (en) * 2011-12-27 2013-07-04 Kadmon Corporation, Llc Methods for treatment of breast cancer nonresponsive to trastuzumab
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はahi1の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
US8980259B2 (en) * 2012-07-20 2015-03-17 Novartis Ag Combination therapy
SG11201500321YA (en) 2012-08-07 2015-04-29 Novartis Ag Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20220110859A (ko) 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
UA124804C2 (uk) * 2016-08-15 2021-11-24 Пфайзер Інк. Піридопіримідинонові інгібітори cdk2/4/6
JP7027699B2 (ja) * 2017-05-09 2022-03-02 住友ゴム工業株式会社 タイヤトレッドおよびタイヤ
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
RU2759746C1 (ru) 2018-03-19 2021-11-17 Тайхо Фармасьютикал Ко., Лтд. Фармацевтическая композиция, включающая алкилсульфат натрия
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
US12486246B2 (en) 2019-12-10 2025-12-02 The Trustees Of Indiana University Replication protein A (RPA)-DNA interaction inhibitors
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
KR20250057151A (ko) 2019-12-30 2025-04-28 데시페라 파마슈티칼스, 엘엘씨 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
KR102195221B1 (ko) 2019-12-31 2020-12-24 서울대학교산학협력단 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물
CN111358952B (zh) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种抗肿瘤药物组合物及其制剂和应用
WO2023092104A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009993A1 (en) * 2001-12-11 2004-01-15 Pharmacia Italia S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2004006846A2 (en) * 2002-07-15 2004-01-22 Exelixis, Inc. Receptor-type kinase modulators and methods of use
WO2005105801A1 (en) * 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
WO2007004698A1 (ja) * 2005-07-06 2007-01-11 Sbc Corporation 漏洩電流検出装置及び漏洩電流検出方法
WO2008021389A2 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1718645A1 (en) 2004-02-18 2006-11-08 Warner-Lambert Company LLC 2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones
EP1931645B1 (en) 2005-10-07 2014-07-16 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
KR20140105621A (ko) 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 PI3Kα의 피리도피리미디논 억제제
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
MX2009002927A (es) * 2006-09-15 2009-03-31 Pfizer Prod Inc Compuestos de pirido (2,3-d)pirimidinona y su uso como inhibidores de la enzima fosfoinositido 3.
KR101626435B1 (ko) 2007-04-10 2016-06-01 엑셀리시스, 인코포레이티드 Pi3k 알파의 피리도피리미디논 억제제를 이용한 암 치료 방법
CN101711249A (zh) 2007-04-11 2010-05-19 埃克塞里艾克西斯公司 作为PI3K-α的抑制剂用于治疗癌症的吡啶并[2,3-D]嘧啶-7-酮化合物
WO2008127678A1 (en) 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
US8481001B2 (en) 2007-04-11 2013-07-09 Exelixis, Inc. Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer
EP2350070A1 (en) 2008-09-30 2011-08-03 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k and mtor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009993A1 (en) * 2001-12-11 2004-01-15 Pharmacia Italia S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2004006846A2 (en) * 2002-07-15 2004-01-22 Exelixis, Inc. Receptor-type kinase modulators and methods of use
WO2005105801A1 (en) * 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
WO2007004698A1 (ja) * 2005-07-06 2007-01-11 Sbc Corporation 漏洩電流検出装置及び漏洩電流検出方法
WO2008021389A2 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer

Also Published As

Publication number Publication date
HK1139863A1 (en) 2010-09-30
EA020022B1 (ru) 2014-08-29
CN101715345A (zh) 2010-05-26
JP2010523670A (ja) 2010-07-15
RS52939B (sr) 2014-02-28
BRPI0810206A2 (pt) 2014-10-21
EP2139484B8 (en) 2013-08-21
EP2139484B1 (en) 2013-07-17
JP2014139217A (ja) 2014-07-31
ES2430614T3 (es) 2013-11-21
CR11100A (es) 2010-01-19
ME00936B (me) 2012-06-20
DK2139484T3 (da) 2013-10-21
JP2014034576A (ja) 2014-02-24
US20100209420A1 (en) 2010-08-19
CO6251254A2 (es) 2011-02-21
EP2139484A1 (en) 2010-01-06
IL201284A (en) 2016-06-30
MA31358B1 (fr) 2010-05-03
EA200970932A1 (ru) 2010-04-30
ZA200906764B (en) 2010-08-25
NZ580110A (en) 2012-06-29
KR20100016354A (ko) 2010-02-12
HN2009003002A (es) 2014-03-24
DOP2009000243A (es) 2010-10-31
PL2139484T3 (pl) 2013-12-31
WO2008124161A1 (en) 2008-10-16
ECSP099724A (es) 2010-03-31
AU2008236562A1 (en) 2008-10-16
CN102727498B (zh) 2016-08-03
EP2139484B9 (en) 2014-06-11
MX2009010930A (es) 2010-01-20
TN2009000400A1 (en) 2010-12-31
KR101626435B1 (ko) 2016-06-01
US8513266B2 (en) 2013-08-20
CA2683641C (en) 2016-08-16
IL201284A0 (en) 2010-05-31
SI2139484T1 (sl) 2013-10-30
PT2139484E (pt) 2013-10-31
UA100979C2 (ru) 2013-02-25
HRP20130688T1 (en) 2013-09-30
CN102727498A (zh) 2012-10-17
CA2683641A1 (en) 2008-10-16
MY150697A (en) 2014-02-28

Similar Documents

Publication Publication Date Title
AU2008236562B2 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
AU2008239668B2 (en) Combination therapies comprising quinoxaline inhibitors of PI3K-alpha for use in the treatment of cancer
AU2008239596B2 (en) Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-alpha for the treatment of cancer
EP2142543B1 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
CA2671982A1 (en) Methods of using mek inhibitors
WO2014177915A1 (en) Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
HK1139863B (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
HK1139941B (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
HK1139948B (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired